Cost analysis of palliative care for terminally ill cancer patients in the UK after switching from weak to strong opioids

PharmacoEconomics

Volumn 14, Issue 3, 1998, Pages 285-297

  Guest, Julian F ^a   Hart, Warren M ^a   Cookson, Ronald F ^b  

^a CATALYST Health Economics Consultants   (United Kingdom)

^b Janssen Cilag Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTIEMETIC AGENT; CARBAMAZEPINE; CODANTHRAMER; DEXAMETHASONE; DIAMORPHINE; DOCUSATE SODIUM; FENTANYL; HALOPERIDOL; LAXATIVE; METOCLOPRAMIDE; MORPHINE DERIVATIVE; NAPROXEN; OMEPRAZOLE; OPIATE AGONIST; RANITIDINE; VALPROIC ACID;

ARTICLE; CANCER PAIN; CANCER PATIENT; DECISION MAKING; DIARRHEA; DRUG EFFICACY; HEALTH CARE COST; HOSPITALIZATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PALLIATIVE THERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUESTIONNAIRE; SUBCUTANEOUS DRUG ADMINISTRATION; TERMINAL DISEASE; TRANSDERMAL DRUG ADMINISTRATION; TREATMENT PLANNING;

ANALGESICS, OPIOID; COSTS AND COST ANALYSIS; DECISION SUPPORT TECHNIQUES; HEALTH CARE COSTS; HUMANS; NEOPLASMS; PALLIATIVE CARE; TERMINALLY ILL;

EID: 0031697071     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199814030-00005     Document Type: Article

References (33)

1. Office of Population Censuses and Surveys. Mortality statistics general: series DH1 no 27 review of the registrar general on deaths in England and Wales 1992. London: Her Majesty's Stationary Office (HMSO), 1994
2. Office of Population Censuses and Surveys. Population trends 74, winter 1993: tables 13 and 14. Death rates by age, sex and selected causes. London: Her Majesty's Stationary Office (HMSO), 1994
3. Melzack R. Humans versus pain: the dilemma of morphine. In: Sicuteri F, editor. Advances in pain research and therapy. New York: Raven Press, 1992: 149-59
4. Fallon M, O'Neill W. Cancer pain. Practitioner 1994; 238: 101-7
5. Field GB, Parry J. Pain control: some aspects of day-to-day management. J Cancer Care 1994; 3: 79-86
6. World Health Organization (WHO). Cancer pain relief. Geneva: WHO, 1986
7. Ahmedzai S, Brooks D. Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy and quality of life. J Pain Symptom Manage 1997; 13 (5): 254-61
8. Normand C. Economics and evaluation of palliative care. Palliat Med 1996; 10: 3-4
9. Le Pen C, Levy E, Ravily V, et al. The cost of treatment dropout in depression: a cost-benefit analysis of fluoxetine vs. tricyclics. J Affect Disord 1994; 31: 1-18
10. 1997 Directory of Hospice & Palliative Care Services in the United Kingdom & Ireland. Hospice information service, Sydenham. London: The Hospice Information Service, 1997
11. Guest JF, Munro V, Cookson R. Comparison of the cost of managing constipation in cancer patients receiving oral morphine or transdermal fentanyl. Eur J Cancer 1997; 33 Suppl. 9: S19
12. Twycross R, Harcourt JMV. The use of laxatives at a palliative care centre. Palliat Med 1991; 5: 27-33
13. Jeal W, Benfield P. Transdermal fentanyl: a review of its pharmacological properties and therapeutic efficacy in pain control. Drugs 1997; 53 (1): 109-38
14. Twycross R. Alimentary symptom control in cancer. In: Twycross RG, Lack SA, editors. Control of alimentary symptoms in far advanced cancer. London: Churchill Livingstone, 1986
15. Ahmedzai S, Brooks DJ. Abstract. European Cancer Conference (ECCO 8). Eur J Cancer 1995; 31 Suppl. 5: S182
16. Monthly index of medical specialities. 1996 ed. London: Haymarket Publications Ltd, 1996
17. Netten A, Dennett J. Unit costs of community care 1996. Kent: Personal Social Services Research Unit, University of Kent, 1996
18. Chartered Institute of Public Finance & Accountancy (CIPFA). Health database. London: CIPFA, 1996
19. Newcampe Medical Ltd. Recommended retail price catalogue. Suffolk: Newcampe Medical Ltd., 1996
20. London Department of Health. Health service price index: appendix 1. London: Her Majesty's Stationary Office (HMSO), 1997
21. UK British Pharmaceutical Index. Middlesex: Intercontinental Medical Statistics Ltd., 1997
22. Hospital Pharmacy Index. Kent: Medicare Audits Ltd., 1997
23. Bloor K, Leese B, Maynard A. The costs of managing severe cancer pain and potential savings from transdermal administration. Eur J Cancer 1994; 30A (4): 463-8
24. Geddes M, Carli S, Ercolanelli M, et al. Colorectal, lung, and breast cancer care during the three years following the diagnosis: a population-based study. Tumori 1996; 82: 210-4
25. Raftery J, Addington-Hall JM, MacDonald LD, et al. A randomized controlled trial of the cost-effectiveness of a district coordinating service for terminally ill cancer patients. Palliat Med 1996; 10: 151-61
26. Doyle C, Stockler M, Pintilie M, et al. Resource implications of palliative chemotherapy for ovarian cancer. J Clin Oncol 1997; 15 (3): 1000-7
27. Sculpher MJ, Sargeant IR, Loizou LA, et al. A cost analysis of Nd: YAG laser ablation versus endoscopic intubation for the palliation of malignant dysphagia. Eur J Cancer 1995; 31A (10): 1640-6
28. Higginson I. Palliative & terminal care: health care needs assessment. Oxford: Radcliffe Medical Press, 1997
29. House of Commons Health Committee. Priority setting in the NHS: purchasing. Vol. 1. London: Her Majesty's Stationary Office (HMSO), 1995
30. Robbins MA, Frankel SJ. Palliative care services: what needs assessment? Palliat Med 1995; 9: 287-93
31. Stjernsward J, Teoh N. Current status of the global cancer control program of the World health Organization. J Pain Symptom Manage 1993; 8 (6): 340-6
32. Scott JF. More money for palliative care? The economics of denial. J Palliat Care 1994; 10 (3): 35-8
33. Goodwin PJ. Economic factors in cancer palliation: methodological considerations. Cancer Treat Rev 1993; 19 Suppl. A: 59-65